BREAKING: Futures Mixed After Trump, Xi MeetAlnylam easily beat Wall Street's third-quarter forecasts on the back of its biggest moneymaker, Amvuttra. Alnylam stock, which has already doubled in 2025, could get a boost from the results.Amvuttra treats forms of transthyretin amyloidosis, a condition in which abnormal protein builds up on the organs. The Food and Drug Administration first approved Alnylam Pharmaceuticals' (ALNY) drug for patients with neuropathy in June 2022. This March, the agency signed off ...